



May 29, 2026

<b>To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 Ref: BSE Scrip Code: 544497</b>	<b>To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL</b>
---	---

**Sub: Outcome of the Board Meeting of ANLON HEALTHCARE LIMITED**

Respected Sir/Madam,

With reference to above captioned subject and in compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015, we hereby submit the Outcome of Board Meeting of the Company held on Friday, May 29, 2026 at the Registered Office of the Company and the following matters inter alia have been considered, approved and taken on record by the Board of Directors:

1. Audited Financial Results (Standalone and Consolidated) of the Company as set out in compliance with Indian Accounting Standards ("IND AS") for the quarter and Financial Year ended March 31, 2026; together with the Report of the Auditor's thereon. **(Enclosed herewith)**
2. Declaration for un-modified opinion on Audited Financial Results (Standalone and Consolidated) for the year ended on March 31, 2026. **(Enclosed herewith)**
3. Statement of deviation or variation for issue proceeds of the Company for the Year ended March 31, 2026. Also enclosed herewith Certificate regarding the utilization of the issue proceeds certified by the Statutory Auditors for the Year ended March 31, 2026. **(Enclosed herewith)**

The Board Meeting commenced at 10:30 A.M. (IST) and concluded at 11:45 P.M. (IST).

You are requested to take the above information on your record

Thanking You.

Yours Faithfully,  
**FOR, ANLON HEALTHCARE LIMITED**

**PUNITKUMAR RASADIA  
MANAGING DIRECTOR  
DIN: 06696258**

---

**ANLON HEALTHCARE LIMITED**

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in

## Independent Auditor's Report

To  
The Members of,  
Anlon Healthcare Limited

### Report on the audit of the Standalone Annual Financial Results

#### Opinion

We have audited the accompanying Standalone Annual Financial Results of Anlon Healthcare Limited (the "Company"), for the year ended March 31, 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Annual Financial Results:

- a) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b) gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit, other comprehensive income, and other financial information of the Company for the year ended March 31, 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013, as amended (the "Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.





## Management and Board of Directors' Responsibilities for the Standalone Annual Financial Results

The Standalone Annual Financial Results has been prepared on the basis of the standalone annual financial statements. The Management and the Board of Directors of the Company are responsible for the preparation and presentation of these Standalone Annual Financial Results that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Annual Financial Results, that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Annual Financial Results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company



## Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Annual Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Standalone Annual Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the Standalone Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- d) Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Standalone Annual Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the Standalone Annual Financial Results, including the disclosures, and whether the Standalone Annual



- f) Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### Other Matter

The Standalone Annual Financial Results includes the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.

For, R V D & Co  
Chartered Accountants  
ICAI Firm Registration No.143936W

Date: May 29, 2026  
Place: Rajkot

  
Kaushal V. Dave  
(Partner)  
Membership No. 174550  
UDIN: 26174550WCAZZK6715



Anlon Healthcare Limited  
U24230GJ2013PLC077543

Address: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot 360005, Gujarat (INDIA)

Standalone Financial Result for the period ended on 31-03-2026

Rs. in Lacs

Sr No	Particulars	Quarter ended			Year ended	
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31 March 2025
		Audited	Un-Audited	Audited	Audited	Audited
I	<b>Income</b>					
	Revenue From Operations	5,542.22	3,557.80	4,892.71	17,649.87	12,028.66
	Other Income	1.25	20.25	4.23	25.39	16.85
	<b>Total Income (I)</b>	<b>5,543.47</b>	<b>3,578.05</b>	<b>4,896.94</b>	<b>17,675.26</b>	<b>12,045.51</b>
II	<b>Expenses</b>					
	Cost of materials consumed	3,323.68	2,610.25	2,790.25	12,976.38	7,128.82
	Changes in inventories of finished goods, Stock in Trade	235.76	(603.10)	(27.72)	(1,691.69)	329.89
	Employee benefits expense	125.16	171.30	124.76	525.12	488.19
	Finance costs	118.29	151.15	91.42	435.29	371.52
	Depreciation and amortization expense	13.09	35.33	82.81	136.31	177.39
	Other expenses	466.34	151.79	286.49	1,226.28	860.88
	<b>Total expenses (II)</b>	<b>4,282.32</b>	<b>2,516.72</b>	<b>3,348.01</b>	<b>13,607.69</b>	<b>9,356.69</b>
III	<b>Profit/(loss) before tax (I-II)</b>	<b>1,261.15</b>	<b>1,061.33</b>	<b>1,548.93</b>	<b>4,067.57</b>	<b>2,688.82</b>
IV	<b>Tax expenses</b>					
	Current tax	148.54	527.73	47.19	1,140.03	757.20
	Deferred tax	133.41	18.40	(12.32)	146.72	(17.46)
	MAT Credit Entitlement	-	-	(150.72)	-	(102.71)
	<b>Total Tax expense (IV)</b>	<b>281.95</b>	<b>546.13</b>	<b>(115.85)</b>	<b>1,286.75</b>	<b>637.03</b>
V	<b>Profit/(loss) after tax for the period (III-IV)</b>	<b>979.20</b>	<b>515.20</b>	<b>1,664.78</b>	<b>2,780.82</b>	<b>2,051.79</b>
VI	<b>Other Comprehensive Income</b>					
	OCI that will be reclassified to P&L	(7.13)	0.34	-	(6.79)	-
	OCI Income tax of items that will be reclassified to P&L	1.70	-	-	1.70	-
	<b>Total Other Comprehensive Income (VI)</b>	<b>(5.43)</b>	<b>0.34</b>	<b>-</b>	<b>(5.09)</b>	<b>-</b>
VII	<b>Total Comprehensive Income for the period (V+VI)</b>	<b>973.77</b>	<b>515.54</b>	<b>1,664.78</b>	<b>2,775.73</b>	<b>2,051.79</b>
VIII	<b>Earnings per equity share</b>					
	Basic	2.15	1.13	5.15	5.93	6.37
	Diluted	2.15	1.13	5.15	5.93	6.37

Place: Rajkot  
Date: 29-May-2026

For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



*[Signature]*  
Punitkumar R. Rasadia  
Managing Director  
6696258

*[Signature]*  
Meet A. Vachhani  
Whole Time Director  
6695053

*[Signature]*  
Naimish D Bhatt  
Chief financial officer

*[Signature]*  
Amita Pragada  
CS & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29/05/2026  
Place: Rajkot

Anlon Healthcare Limited  
U24230GJ2013PLC077543

Registered office: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot 360005, Gujarat (INDIA)  
Standalone Balance Sheet as at 31-03-2026


Rs. in Lacs

Particulars	As at	As at
	31 March 2026	31 March 2025
	Audited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	4,036.29	2,281.90
Financial Assets		
Investments	1,016.52	-
Other non current assets	694.60	-
<b>Total Non-current Assets</b>	<b>5,747.41</b>	<b>2,281.90</b>
<b>Current assets</b>		
Inventories	7,558.95	5,026.31
Financial Assets		
Investments	1.00	90.91
Trade receivables	10,417.14	7,499.87
Cash and cash equivalents	341.29	144.96
Loans	19.46	227.96
Other financial assets	-	138.04
Other current assets	7,635.25	2,720.05
<b>Total Current Assets</b>	<b>25,973.09</b>	<b>15,848.10</b>
<b>Total Assets</b>	<b>31,720.50</b>	<b>18,130.00</b>
<b>EQUITY and LIABILITIES</b>		
Equity Share Capital	5,315.15	3,985.15
Other Equity	15,662.12	4,057.02
<b>Total Equity</b>	<b>20,977.27</b>	<b>8,042.17</b>
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	248.06	3,835.70
Provisions	36.68	24.40
Deferred tax liabilities net	367.52	222.50
<b>Total Non-current liabilities</b>	<b>652.26</b>	<b>4,082.60</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	4,311.87	2,819.74
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	7.66	47.68
- total outstanding dues of others	3,934.64	1,916.67
Other current liabilities	632.50	433.48
Provisions - current	60.63	30.46
Current Tax Liabilities, net	1,143.67	757.20
<b>Total Current liabilities</b>	<b>10,090.97</b>	<b>6,005.23</b>
<b>Total liabilities</b>	<b>10,743.23</b>	<b>10,087.83</b>
<b>Total Equity and Liabilities</b>	<b>31,720.50</b>	<b>18,130.00</b>


Place: Rajkot  
Date: May 29, 2026

For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



  
Punithkumar R. Rasadia  
Managing Director  
6696258

  
Naimish Bhatt  
Chief financial officer

  
Meef A. Vachhani  
Whole Time Director  
6695053

  
Amita Pragada  
Company Secretary & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29 / 05 / 2026  
Place: Rajkot

Particulars	Rs. in Lacs	
	For Period ended 31 March 2026 Audited	For Period ended 31 March 2025 Audited
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit for the year	2,780.82	2,051.79
<b>Adjustments for:</b>		
Depreciation and amortisation	136.31	177.39
(Gain)/Loss on disposal of property, plant and equipment	-	(8.12)
(Gain)/Loss on disposal of Investments	-	2.35
(Gain)/Loss on investments measured at fair value through profit and loss	-	30.46
Provision for Income tax	1,286.75	7.91
Finance Cost	435.29	371.52
Interest Income	(20.86)	-
<b>Operating profit before working capital changes</b>	<b>4,618.31</b>	<b>2,633.30</b>
<b>Adjustment for (increase) / decrease in operating assets</b>		
Trade receivables	(2,917.27)	(3,626.82)
Loans & Advances	208.49	13.80
Other financial assets	138.04	(82.23)
Inventories	(2,532.64)	(854.96)
Other assets	(5,609.80)	(1,207.30)
<b>Adjustment for (Increase) / decrease in operating liabilities</b>		
Trade payables	1,977.94	(34.88)
Employee benefit obligation	-	-
Other Liabilities	199.03	415.98
Provisions	35.66	(46.59)
<b>Cash generated from operations</b>	<b>(3,882.24)</b>	<b>(2,789.70)</b>
Income tax paid (net)	(753.57)	534.52
<b>Net cash generated by operating activities</b>	<b>(4,635.81)</b>	<b>(2,255.18)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant and equipment	(1,890.70)	(52.93)
Purchase of other Investment	(926.61)	-
Proceeds from disposal of property, plant and equipment	-	323.34
Interest received	20.86	8.12
<b>Net cash (used in) / generated by investing activities</b>	<b>(2,796.45)</b>	<b>278.53</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from short term borrowings	1,492.14	(32.76)
Repayment of long term borrowings	(3,587.64)	(1,588.82)
Finance cost	(435.29)	(371.52)
Issue of Equity Shares	10,159.37	3,887.25
<b>Net cash used in financing activities</b>	<b>7,628.58</b>	<b>1,894.15</b>
Net increase / (decrease) in cash and cash equivalents	196.32	(82.50)
Cash and cash equivalents at the beginning of the year	144.96	227.45
Exchange gain loss on Cash and cash equivalents	-	-
<b>Cash and cash equivalents at the end of the year</b>	<b>341.28</b>	<b>144.95</b>
<b>Reconciliation of Cash and Cash Equivalents with Balance Sheet:</b>		
Cash and cash equivalents includes		
Cash on hand	327.60	144.09
Balances with Banks	13.69	0.85

Place: Rajkot  
Date: May 29, 2026

Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



Purifikumar R. Rasadia  
Managing Director  
6696258

Naimish Bhatt  
Chief financial officer

Meet A. Vachhani  
Whole Time Director  
6695053  
Amita Pragada  
Company Secretary & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29 / 05 / 2026  
Place: Rajkot

**1 Corporate information**

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

**2 Basis of Preparation**

The Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ('Ind AS'), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The standalone financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The standalone financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

**3 Segment Reporting**

Anlon Healthcare Limited is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

**4 The Status of investor complaints received by the company is as follows :**

During Quarter 4 of FY 2025–26, the Company did not receive any complaints from investors. Accordingly, there were no pending investor complaints as on the end of the quarter.

**5 List of Group Companies or Subsidiary company**

Bizotic Lifescience Private Limited.  
Apiqo Organics Private Limited.

**6 The above financial results of Anlon Healthcare Limited (the "Company") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on May 29, 2026, respectively**

**7 The figures for the previous year have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current year's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current year's financial statements.**

**8 Other Expenses includes operational, statutory, and administrative expenses Power Fuel,Packing Material,Factory Electricity Expenses,Freight Inward,Advertisement Expenses,Canteen and -Import Duty Expenses Etc**

**9 IPO-related expenses incurred by the Company, to the extent they represent incremental costs directly attributable to the issuance of equity shares, have been adjusted against Securities Premium in accordance with Ind AS 32. Other expenses, not directly attributable to the issue of equity instruments, have been recognised in the Statement of Profit and Loss.**

For and on behalf of Board of Directors,  
Anlon Healthcare Limited

  
Punitkumar R. Rasadia  
Managing Director



Place: Rajkot  
Date: May 29, 2026

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29/05/2026  
Place: Rajkot

## Independent Auditor's Report

To  
The Members of,  
Anlon Healthcare Limited

### Report on the audit of the Consolidated Annual Financial Results

#### Opinion

We have audited the accompanying Consolidated Annual Financial Results of Anlon Healthcare Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") for the year ended March 31, 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Annual Financial Results:


- i. Includes results of:

S. No.	Name of Entity	Relationship
1	Anlon Healthcare Limited	Holding Company
2	Bizotic Lifescience Private Limited	Subsidiary Company
3	Apiqo Organics Private Limited	Subsidiary Company

- ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the consolidated net profit, consolidated other comprehensive income, and other financial information of the Group for the year ended March 31, 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013, as amended (the "Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results" section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of



Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

### **Management and Board of Directors' Responsibilities for the Consolidated Annual Financial Results**

The Consolidated Annual Financial Results have been prepared on the basis of the annual consolidated financial statements. The Management and the Board of Directors of the Holding Company are responsible for the preparation and presentation of the Consolidated Annual Financial Results that gives a true and fair view of the consolidated net profit and other comprehensive income of the Group and other financial information in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Annual Financial Results, that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Annual Financial Results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Annual Financial Results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the respective companies or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the Consolidated Annual Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Consolidated Annual Financial Results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and the Board of Directors.
- Conclude on the appropriateness of the Management and the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's report to the related disclosures in the Consolidated Annual Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Annual Financial Results, including the disclosures, and whether the Consolidated Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Consolidated Annual Financial Results. For the other entities included in the Consolidated Annual Financial Results, which have been audited by other auditor, such other auditor remains responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in paragraphs (1) and (2) of the "Other Matters" section of our report.

We communicate with those charged with governance of the Holding Company and the subsidiaries included in the Consolidated Annual Financial Results of which we are independent auditors, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



"Level-6", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005

+91 6356 797 885

0281 - 2991685

office@cakda.in

www.cakda.in

We also provide those charged with governance of the Holding Company with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedure in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

### Other Matters

1. The accompanying Consolidated Annual Financial Results includes:


- a) The audited financial results and other financial information, in respect of 2 (two) subsidiaries, whose audited financial statements include following

(Amount in Lakhs )

Name of Subsidiary	Total Assets	Total Revenue	Net Profit After Tax	Total Comprehensive Income	Net Cashflow
Apiqo Organics Private Limited.	5808.62	2180.83	131.60	131.60	9.59
Bizotic Lifescience Private Limited.	2208.66	0.00	(3.61)	(3.61)	(3.96)

- b) The financial statements of Bizotic Lifescience Private Limited and Apiqo Organics Private Limited (the “subsidiaries”) included in the aforesaid consolidated financial results have been audited by us.


Our opinion on the Statement is not modified in respect of the above matter.



2. The Consolidated Annual Financial Results includes the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.

For, R V D & Co  
Chartered Accountants  
ICAI Firm Registration No.143936W

Date: May 29, 2026  
Place: Rajkot

  
Kaushal V. Dave  
(Partner)  
Membership No. 174550  
UDIN: 26174550PMSTWU9603



Rs. in Lakhs (Unless stated otherwise)

Sr No	Particulars	Quarter Ended			Year ended	
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31 March 2025
		Audited	Un-Audited	Audited	Audited	Audited
I	<b>Income</b>					
	Revenue From Operations	5,088.91	3,557.80	4,892.71	17,196.56	12,028.66
	Other Income	1.40	20.25	4.23	25.54	16.85
	<b>Total Income (I)</b>	<b>5,090.31</b>	<b>3,578.05</b>	<b>4,896.94</b>	<b>17,222.10</b>	<b>12,045.51</b>
II	<b>Expenses</b>					
	Cost of materials consumed	5,278.25	2,610.25	2,790.25	14,930.95	7,128.82
	Changes in inventories of finished goods, Stock in Trade and work in progress	(2,493.40)	(603.10)	(27.72)	(4,420.85)	329.89
	Employee benefits expense	154.08	171.30	124.76	554.04	488.19
	Finance costs	57.07	151.15	91.42	374.07	371.52
	Depreciation and amortization expense	29.19	35.33	82.81	152.41	177.39
	Other expenses	620.82	151.79	286.49	1,380.76	860.88
	<b>Total expenses (II)</b>	<b>3,646.01</b>	<b>2,516.72</b>	<b>3,348.01</b>	<b>12,971.38</b>	<b>9,356.69</b>
III	<b>Profit/(loss) before tax (I-II)</b>	<b>1,444.30</b>	<b>1,061.33</b>	<b>1,548.93</b>	<b>4,250.72</b>	<b>2,688.82</b>
IV	<b>Tax expenses</b>					
	Current tax	188.78	527.73	47.19	1,180.27	757.20
	Deferred tax	148.33	18.40	(12.32)	161.64	(17.46)
	MAT Credit Entitlement	-	-	(150.72)	-	(102.71)
	<b>Total Tax expense (IV)</b>	<b>337.11</b>	<b>546.13</b>	<b>(115.85)</b>	<b>1,341.91</b>	<b>637.03</b>
V	<b>Profit/(loss) after tax for the period (III-IV)</b>	<b>1,107.19</b>	<b>515.20</b>	<b>1,664.78</b>	<b>2,908.81</b>	<b>2,051.79</b>
VI	<b>Other Comprehensive Income</b>					
	OCI that will be reclassified to P&L	(7.13)	0.34	-	(6.79)	-
	OCI Income tax of items that will be reclassified to P&L	1.70	-	-	1.70	-
	<b>Total Other Comprehensive Income (VI)</b>	<b>(5.43)</b>	<b>0.34</b>	<b>-</b>	<b>(5.09)</b>	<b>-</b>
VII	<b>Total Comprehensive Income for the period (V+VI)</b>	<b>1,101.76</b>	<b>515.54</b>	<b>1,664.78</b>	<b>2,903.72</b>	<b>2,051.79</b>
VIII	<b>Profit/(loss) after tax for the period (III-IV) attributable to:</b>					
	-Owners of the company	1,049.76	515.20	1,664.78	2,851.38	2,051.79
	-Non-Controlling Interests	57.43	-	-	57.43	-
		<b>1,107.19</b>	<b>515.20</b>	<b>1,664.78</b>	<b>2,908.81</b>	<b>2,051.79</b>
IX	<b>Total Other Comprehensive Income (VI) attributable to:</b>					
	-Owners of the company	(5.43)	0.34	-	(5.09)	-
	-Non-Controlling Interests	-	-	-	-	-
		<b>(5.43)</b>	<b>0.34</b>	<b>-</b>	<b>(5.09)</b>	<b>-</b>
X	<b>Total Comprehensive Income for the period (V+VI) attributable to:</b>					
	-Owners of the company	1,044.34	515.54	1,664.78	2,846.29	2,051.79
	-Non-Controlling Interests	57.43	-	-	57.43	-
		<b>1,101.76</b>	<b>515.54</b>	<b>1,664.78</b>	<b>2,903.72</b>	<b>2,051.79</b>
XI	<b>Details of Equity Share Capital</b>					
	Paid-Up Equity Share Capital	5,315.15	5,315.15	3,985.15	5,315.15	3,985.15
	Face Value of Equity Share Capital (Per Value)	10.00	10.00	10.00	10.00	10.00
	<b>Other Equity</b>				17,707.71	4,057.02
XII	<b>Earnings per equity share</b>					
	Basic	2.33	1.13	5.15	6.11	6.37
	Diluted	2.33	1.13	5.15	6.11	6.37

Place: Rajkot  
Date: 29-May-2026

For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



Punitkumar R. Rasadia  
Managing Director  
6696258

Naimish D Bhatt  
Chief financial officer

Meet A. Vachhani  
Whole Time Director  
6695053

Amrita Pragada  
CS & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29/05/2026  
Place: Rajkot

**Anlon Healthcare Limited**

U24230GJ2013PLC077543

Registered office: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road,

Consolidated Balance Sheet as at 31-03-2026

Rs. in Lacs (Unless stated otherwise)

Particulars	As at	As at
	31 March 2026	31 March 2025
	Audited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	5,771.36	2,281.90
Goodwill	4.79	-
Financial Assets		
Investments	97.89	-
Other non current assets	696.44	-
<b>Total Non-current Assets</b>	<b>6,570.48</b>	<b>2,281.90</b>
<b>Current assets</b>		
Inventories	11,316.34	5,026.31
Financial Assets		
Investments	1.00	90.91
Trade receivables	10,367.77	7,499.87
Cash and cash equivalents	436.59	144.96
Loans	19.46	227.96
Other financial assets	-	138.04
Other current assets	8,684.87	2,720.05
<b>Total Current Assets</b>	<b>30,826.03</b>	<b>15,848.10</b>
<b>Total Assets</b>	<b>37,396.51</b>	<b>18,130.00</b>
<b>EQUITY and LIABILITIES</b>		
Equity Share Capital	5,315.15	3,985.15
Other Equity	17,707.71	4,057.02
<b>Total Equity</b>	<b>23,022.86</b>	<b>8,042.17</b>
Non controlling interests	2,456.56	-
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	609.37	3,835.70
Provisions	36.68	24.40
Deferred tax liabilities net	514.47	222.50
<b>Total Non-current liabilities</b>	<b>1,160.52</b>	<b>4,082.60</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	3,755.90	2,819.74
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	7.66	47.68
- total outstanding dues of others	4,211.57	1,916.67
Other current liabilities	1,395.54	433.48
Provisions - current	66.06	30.46
Current Tax Liabilities, net	1,319.84	757.20
<b>Total Current liabilities</b>	<b>10,756.57</b>	<b>6,005.23</b>
<b>Total liabilities</b>	<b>11,917.09</b>	<b>10,087.83</b>
<b>Total Equity and Liabilities</b>	<b>37,396.51</b>	<b>18,130.00</b>

Place: Rajkot  
Date: 29-May-2026For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)Punitkumar R. Rasadia  
Managing Director  
6696258  
Naimish D Bhatt  
Chief financial officer  
Meet A Vachhani  
Whole Time Director  
6695053  
Amita Pragada  
Company Secretary & Compliance OfficerSIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936WDate: 29/05/2026  
Place: Rajkot

Rs. in Lacs (Unless stated otherwise)

Particulars	Note No	Rs. in Lacs (Unless stated otherwise)	
		For Period ended 31 March 2026	For Period ended 31 March 2025
		Audited	Audited
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit for the year		2,908.81	2,051.79
<b>Adjustments for:</b>			
Depreciation and amortisation		152.41	177.39
(Gain)/Loss on disposal of property, plant and equipment		-	(8.12)
(Gain)/Loss on disposal of investments		-	2.35
(Gain)/Loss on investments measured at fair value through profit and loss		-	30.46
Provision for Income tax		1,341.91	-
Provision for Gratuity		25.77	7.91
Finance Cost		374.06	371.52
Interest Income		(20.97)	-
<b>Operating profit before working capital changes</b>		<b>4,781.99</b>	<b>2,633.30</b>
<b>Adjustment for (increase) / decrease in operating assets</b>			
Trade receivables		(2,867.90)	(3,626.82)
Loans & Advances		208.49	13.80
Other financial assets		138.04	(82.23)
Inventories		(6,290.03)	(854.96)
Other assets		(6,661.26)	(1,207.30)
<b>Adjustment for (Increase) / decrease in operating liabilities</b>			
Trade payables		2,254.88	(34.88)
Employee benefit obligation		-	-
Other Liabilities		962.06	415.98
Provisions		15.32	(46.59)
<b>Cash generated from operations</b>		<b>(7,458.41)</b>	<b>(2,789.70)</b>
Income tax paid (net)		(485.59)	534.52
<b>Net cash generated by operating activities</b>		<b>(7,944.00)</b>	<b>(2,255.18)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Purchase of property, plant and equipment		(3,641.88)	(52.93)
Purchase of Goodwill		(4.79)	-
Purchase of other Investment		(7.98)	-
Proceeds from disposal of property, plant and equipment		-	323.34
Interest received		20.97	8.12
<b>Net cash (used in) / generated by investing activities</b>		<b>(3,633.68)</b>	<b>278.53</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Proceeds from short term borrowings		936.17	(32.76)
Proceeds from long term borrowings		(3,226.33)	-
Repayment of long term borrowings		-	(1,588.82)
Finance cost		(374.06)	(371.52)
Issue of Equity Shares		12,134.40	3,887.25
Non controlling interests		2,399.13	-
<b>Net cash used in financing activities</b>		<b>11,869.31</b>	<b>1,894.15</b>
Net increase / (decrease) in cash and cash equivalents		291.63	(82.50)
Cash and cash equivalents at the beginning of the year		144.96	227.45
Cash and cash equivalents acquired from subsidiaries		-	-
<b>Cash and cash equivalents at the end of the year</b>		<b>436.59</b>	<b>144.95</b>

Particulars	For Period ended 31 March 2026	For Period ended 31 March 2025
Reconciliation of Cash and Cash Equivalents with Balance Sheet:		
Cash and cash equivalents includes		
Cash on hand	358.24	144.09
Balances with Banks	78.35	0.85

Place: Rajkot  
Date: 29-May-2026

For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



*[Signature]*  
Pankitkumar R. Rasadia  
Managing Director  
6696258

*[Signature]*  
Naimish D Bhatt  
Chief financial officer

*[Signature]*  
Meet A. Vachhani  
Whole Time Director  
6695053  
*[Signature]*  
Amita Pragada  
Company Secretary & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29 / 05 / 2026

**1 Corporate information**

The consolidated financial statements comprise financial statements of Anlon Healthcare Limited (the "Company") and its subsidiaries (collectively the "Group") for the year ended 31st March, 2026

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

**2 Basis of Preparation**

The Consolidated Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ('Ind AS'), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The Consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The Consolidated financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

**3 Segment Reporting**

Anlon Healthcare Limited and its Subsidiaries is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

**4 The Status of investor complaints received by the company is as follows :**

During Quarter 4 of FY 2025–26, the Company did not receive any complaints from investors. Accordingly, there were no pending investor complaints as on the end of the quarter.

**5 List of Group Companies or Subsidiary company**


Bizotic Lifescience Private Limited.  
Apiqo Organics Private Limited.

**6 IPO-related expenses incurred by the Company, to the extent they represent incremental costs directly attributable to the issuance of equity shares, have been adjusted against Securities Premium in accordance with Ind AS 32. Other expenses, not directly attributable to the issue of equity instruments, have been recognised in the Statement of Profit and Loss.**

**7 The figures for the previous year have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current year's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current year's financial statements.**

**8 Other Expenses includes operational, statutory, and administrative expenses Power Fuel, Packing Material, Factory Electricity Expenses, Freight Inward, Advertisement Expenses, Canteen and -Import Duty Expenses Etc**

For and on behalf of Board of Directors,  
Anlon Healthcare Limited

  
Punitkumar R. Rasadia  
Managing Director



Place: Rajkot  
Date: 29-May-2026

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29 / 05 / 2026  
Place : Rajkot

## Independent Auditor's Report

To  
The Members of,  
Anlon Healthcare Limited

### Report on the audit of the Standalone Annual Financial Results

#### Opinion

We have audited the accompanying Standalone Annual Financial Results of Anlon Healthcare Limited (the "Company"), for the year ended March 31, 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Annual Financial Results:

- a) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b) gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit, other comprehensive income, and other financial information of the Company for the year ended March 31, 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013, as amended (the "Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.





## Management and Board of Directors' Responsibilities for the Standalone Annual Financial Results

The Standalone Annual Financial Results has been prepared on the basis of the standalone annual financial statements. The Management and the Board of Directors of the Company are responsible for the preparation and presentation of these Standalone Annual Financial Results that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Annual Financial Results, that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Annual Financial Results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company



## Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Annual Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Standalone Annual Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the Standalone Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- d) Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Standalone Annual Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the Standalone Annual Financial Results, including the disclosures, and whether the Standalone Annual



- f) Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### Other Matter

The Standalone Annual Financial Results includes the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.

For, R V D & Co  
Chartered Accountants  
ICAI Firm Registration No.143936W

Date: May 29, 2026  
Place: Rajkot

  
Kaushal V. Dave  
(Partner)  
Membership No. 174550  
UDIN: 26174550WCAZZK6715



Anlon Healthcare Limited  
U24230GJ2013PLC077543

Address: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot 360005, Gujarat (INDIA)

Standalone Financial Result for the period ended on 31-03-2026

Rs. in Lacs

Sr No	Particulars	Quarter ended			Year ended	
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31 March 2025
		Audited	Un-Audited	Audited	Audited	Audited
I	<b>Income</b>					
	Revenue From Operations	5,542.22	3,557.80	4,892.71	17,649.87	12,028.66
	Other Income	1.25	20.25	4.23	25.39	16.85
	<b>Total Income (I)</b>	<b>5,543.47</b>	<b>3,578.05</b>	<b>4,896.94</b>	<b>17,675.26</b>	<b>12,045.51</b>
II	<b>Expenses</b>					
	Cost of materials consumed	3,323.68	2,610.25	2,790.25	12,976.38	7,128.82
	Changes in inventories of finished goods, Stock in Trade	235.76	(603.10)	(27.72)	(1,691.69)	329.89
	Employee benefits expense	125.16	171.30	124.76	525.12	488.19
	Finance costs	118.29	151.15	91.42	435.29	371.52
	Depreciation and amortization expense	13.09	35.33	82.81	136.31	177.39
	Other expenses	466.34	151.79	286.49	1,226.28	860.88
	<b>Total expenses (II)</b>	<b>4,282.32</b>	<b>2,516.72</b>	<b>3,348.01</b>	<b>13,607.69</b>	<b>9,356.69</b>
III	<b>Profit/(loss) before tax (I-II)</b>	<b>1,261.15</b>	<b>1,061.33</b>	<b>1,548.93</b>	<b>4,067.57</b>	<b>2,688.82</b>
IV	<b>Tax expenses</b>					
	Current tax	148.54	527.73	47.19	1,140.03	757.20
	Deferred tax	133.41	18.40	(12.32)	146.72	(17.46)
	MAT Credit Entitlement	-	-	(150.72)	-	(102.71)
	<b>Total Tax expense (IV)</b>	<b>281.95</b>	<b>546.13</b>	<b>(115.85)</b>	<b>1,286.75</b>	<b>637.03</b>
V	<b>Profit/(loss) after tax for the period (III-IV)</b>	<b>979.20</b>	<b>515.20</b>	<b>1,664.78</b>	<b>2,780.82</b>	<b>2,051.79</b>
VI	<b>Other Comprehensive Income</b>					
	OCI that will be reclassified to P&L	(7.13)	0.34	-	(6.79)	-
	OCI Income tax of items that will be reclassified to P&L	1.70	-	-	1.70	-
	<b>Total Other Comprehensive Income (VI)</b>	<b>(5.43)</b>	<b>0.34</b>	<b>-</b>	<b>(5.09)</b>	<b>-</b>
VII	<b>Total Comprehensive Income for the period (V+VI)</b>	<b>973.77</b>	<b>515.54</b>	<b>1,664.78</b>	<b>2,775.73</b>	<b>2,051.79</b>
VIII	<b>Earnings per equity share</b>					
	Basic	2.15	1.13	5.15	5.93	6.37
	Diluted	2.15	1.13	5.15	5.93	6.37

Place: Rajkot  
Date: 29-May-2026

For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



*Punatkumar R. Rasadia*  
Punatkumar R. Rasadia  
Managing Director  
6696258

*Namish D Bhatt*  
Namish D Bhatt  
Chief financial officer

*Meer A. Vachhani*  
Meer A. Vachhani  
Whole Time Director  
6695053

*Amita Pragada*  
Amita Pragada  
CS & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29/05/2026  
Place: Rajkot

Anlon Healthcare Limited  
U24230GJ2013PLC077543

Registered office: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot 360005, Gujarat (INDIA)  
Standalone Balance Sheet as at 31-03-2026

Rs. in Lacs

Particulars	As at	As at
	31 March 2026	31 March 2025
	Audited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	4,036.29	2,281.90
Financial Assets		
Investments	1,016.52	-
Other non current assets	694.60	-
<b>Total Non-current Assets</b>	<b>5,747.41</b>	<b>2,281.90</b>
<b>Current assets</b>		
Inventories	7,558.95	5,026.31
Financial Assets		
Investments	1.00	90.91
Trade receivables	10,417.14	7,499.87
Cash and cash equivalents	341.29	144.96
Loans	19.46	227.96
Other financial assets	-	138.04
Other current assets	7,635.25	2,720.05
<b>Total Current Assets</b>	<b>25,973.09</b>	<b>15,848.10</b>
<b>Total Assets</b>	<b>31,720.50</b>	<b>18,130.00</b>
<b>EQUITY and LIABILITIES</b>		
Equity Share Capital	5,315.15	3,985.15
Other Equity	15,662.12	4,057.02
<b>Total Equity</b>	<b>20,977.27</b>	<b>8,042.17</b>
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	248.06	3,835.70
Provisions	36.68	24.40
Deferred tax liabilities net	367.52	222.50
<b>Total Non-current liabilities</b>	<b>652.26</b>	<b>4,082.60</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	4,311.87	2,819.74
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	7.66	47.68
- total outstanding dues of others	3,934.64	1,916.67
Other current liabilities	632.50	433.48
Provisions - current	60.63	30.46
Current Tax Liabilities, net	1,143.67	757.20
<b>Total Current liabilities</b>	<b>10,090.97</b>	<b>6,005.23</b>
<b>Total liabilities</b>	<b>10,743.23</b>	<b>10,087.83</b>
<b>Total Equity and Liabilities</b>	<b>31,720.50</b>	<b>18,130.00</b>

Place: Rajkot  
Date: May 29, 2026

For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



*[Signature]*  
Punitkumar R. Rasadia  
Managing Director  
6696258

*[Signature]*  
Naimish Bhatt  
Chief financial officer

*[Signature]*  
Meef A. Vachhani  
Whole Time Director  
6695053

*[Signature]*  
Amita Pragada  
Company Secretary & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29 / 05 / 2026  
Place: Rajkot

Particulars	Rs. in Lacs	
	For Period ended 31 March 2026	For Period ended 31 March 2025
	Audited	Audited
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit for the year	2,780.82	2,051.79
<b>Adjustments for:</b>		
Depreciation and amortisation	136.31	177.39
(Gain)/Loss on disposal of property, plant and equipment	-	(8.12)
(Gain)/Loss on disposal of Investments	-	2.35
(Gain)/Loss on investments measured at fair value through profit and loss	-	30.46
Provision for Income tax	1,286.75	7.91
Finance Cost	435.29	371.52
Interest Income	(20.86)	-
<b>Operating profit before working capital changes</b>	<b>4,618.31</b>	<b>2,633.30</b>
<b>Adjustment for (increase) / decrease in operating assets</b>		
Trade receivables	(2,917.27)	(3,626.82)
Loans & Advances	208.49	13.80
Other financial assets	138.04	(82.23)
Inventories	(2,532.64)	(854.96)
Other assets	(5,609.80)	(1,207.30)
<b>Adjustment for (Increase) / decrease in operating liabilities</b>		
Trade payables	1,977.94	(34.88)
Employee benefit obligation	-	-
Other Liabilities	199.03	415.98
Provisions	35.66	(46.59)
<b>Cash generated from operations</b>	<b>(3,882.24)</b>	<b>(2,789.70)</b>
Income tax paid (net)	(753.57)	534.52
<b>Net cash generated by operating activities</b>	<b>(4,635.81)</b>	<b>(2,255.18)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant and equipment	(1,890.70)	(52.93)
Purchase of other Investment	(926.61)	-
Proceeds from disposal of property, plant and equipment	-	323.34
Interest received	20.86	8.12
<b>Net cash (used in) / generated by investing activities</b>	<b>(2,796.45)</b>	<b>278.53</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from short term borrowings	1,492.14	(32.76)
Repayment of long term borrowings	(3,587.64)	(1,588.82)
Finance cost	(435.29)	(371.52)
Issue of Equity Shares	10,159.37	3,887.25
<b>Net cash used in financing activities</b>	<b>7,628.58</b>	<b>1,894.15</b>
Net increase / (decrease) in cash and cash equivalents	196.32	(82.50)
Cash and cash equivalents at the beginning of the year	144.96	227.45
Exchange gain loss on Cash and cash equivalents	-	-
<b>Cash and cash equivalents at the end of the year</b>	<b>341.28</b>	<b>144.95</b>

Particulars	For Period ended 31 March 2026	For Period ended 31 March 2025
Reconciliation of Cash and Cash Equivalents with Balance Sheet:		
Cash and cash equivalents includes		
Cash on hand	327.60	144.09
Balances with Banks	13.69	0.85

Place: Rajkot  
Date: May 29, 2026

Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



*Purifkumar R. Rasadia*  
Purifkumar R. Rasadia  
Managing Director  
6696258

*Naimish Bhatt*  
Naimish Bhatt  
Chief financial officer

*Meet A. Vachhani*  
Meet A. Vachhani  
Whole Time Director  
6695053

*Amita Pragada*  
Amita Pragada  
Company Secretary & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29 / 05 / 2026  
Place: Rajkot

**1 Corporate information**

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

**2 Basis of Preparation**

The Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ('Ind AS'), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The standalone financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The standalone financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

**3 Segment Reporting**

Anlon Healthcare Limited is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

**4 The Status of investor complaints received by the company is as follows :**

During Quarter 4 of FY 2025–26, the Company did not receive any complaints from investors. Accordingly, there were no pending investor complaints as on the end of the quarter.

**5 List of Group Companies or Subsidiary company**

Bizotic Lifescience Private Limited.  
Apiqo Organics Private Limited.


**6 The above financial results of Anlon Healthcare Limited (the "Company") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on May 29, 2026, respectively**

**7 The figures for the previous year have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current year's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current year's financial statements.**

**8 Other Expenses includes operational, statutory, and administrative expenses Power Fuel,Packing Material,Factory Electricity Expenses,Freight Inward,Advertisement Expenses,Canteen and -Import Duty Expenses Etc**

**9 IPO-related expenses incurred by the Company, to the extent they represent incremental costs directly attributable to the issuance of equity shares, have been adjusted against Securities Premium in accordance with Ind AS 32. Other expenses, not directly attributable to the issue of equity instruments, have been recognised in the Statement of Profit and Loss.**

For and on behalf of Board of Directors,  
Anlon Healthcare Limited

  
Punitkumar R. Rasadia  
Managing Director



Place: Rajkot  
Date: May 29, 2026

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29 / 05 / 2026  
Place: Rajkot

## Independent Auditor's Report

To  
The Members of,  
Anlon Healthcare Limited

### Report on the audit of the Consolidated Annual Financial Results

#### Opinion

We have audited the accompanying Consolidated Annual Financial Results of Anlon Healthcare Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") for the year ended March 31, 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Annual Financial Results:

- i. Includes results of:

S. No.	Name of Entity	Relationship
1	Anlon Healthcare Limited	Holding Company
2	Bizotic Lifescience Private Limited	Subsidiary Company
3	Apiqo Organics Private Limited	Subsidiary Company

- ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the consolidated net profit, consolidated other comprehensive income, and other financial information of the Group for the year ended March 31, 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013, as amended (the "Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results" section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of



"Level-6", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005

Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

### **Management and Board of Directors' Responsibilities for the Consolidated Annual Financial Results**

The Consolidated Annual Financial Results have been prepared on the basis of the annual consolidated financial statements. The Management and the Board of Directors of the Holding Company are responsible for the preparation and presentation of the Consolidated Annual Financial Results that gives a true and fair view of the consolidated net profit and other comprehensive income of the Group and other financial information in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Annual Financial Results, that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Annual Financial Results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Annual Financial Results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the respective companies or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results**


Our objectives are to obtain reasonable assurance about whether the Consolidated Annual Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Consolidated Annual Financial Results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and the Board of Directors.
- Conclude on the appropriateness of the Management and the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's report to the related disclosures in the Consolidated Annual Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Annual Financial Results, including the disclosures, and whether the Consolidated Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Consolidated Annual Financial Results. For the other entities included in the Consolidated Annual Financial Results, which have been audited by other auditor, such other auditor remains responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in paragraphs (1) and (2) of the "Other Matters" section of our report.

We communicate with those charged with governance of the Holding Company and the subsidiaries included in the Consolidated Annual Financial Results of which we are independent auditors, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



"Level-6", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005

+91 6356 797 885

0281 - 2991685

office@cakda.in

www.cakda.in

We also provide those charged with governance of the Holding Company with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedure in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

### Other Matters

1. The accompanying Consolidated Annual Financial Results includes:


- a) The audited financial results and other financial information, in respect of 2 (two) subsidiaries, whose audited financial statements include following

(Amount in Lakhs )

Name of Subsidiary	Total Assets	Total Revenue	Net Profit After Tax	Total Comprehensive Income	Net Cashflow
Apiqo Organics Private Limited.	5808.62	2180.83	131.60	131.60	9.59
Bizotic Lifescience Private Limited.	2208.66	0.00	(3.61)	(3.61)	(3.96)

- b) The financial statements of Bizotic Lifescience Private Limited and Apiqo Organics Private Limited (the “subsidiaries”) included in the aforesaid consolidated financial results have been audited by us.


Our opinion on the Statement is not modified in respect of the above matter.



2. The Consolidated Annual Financial Results includes the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.

For, R V D & Co  
Chartered Accountants  
ICAI Firm Registration No.143936W

Date: May 29, 2026  
Place: Rajkot

  
Kaushal V. Dave  
(Partner)  
Membership No. 174550  
UDIN: 26174550PMSTWU9603



Rs. in Lakhs (Unless stated otherwise)

Sr No	Particulars	Quarter Ended			Year ended	
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31 March 2025
		Audited	Un-Audited	Audited	Audited	Audited
I	<b>Income</b>					
	Revenue From Operations	5,088.91	3,557.80	4,892.71	17,196.56	12,028.66
	Other Income	1.40	20.25	4.23	25.54	16.85
	<b>Total Income (I)</b>	<b>5,090.31</b>	<b>3,578.05</b>	<b>4,896.94</b>	<b>17,222.10</b>	<b>12,045.51</b>
II	<b>Expenses</b>					
	Cost of materials consumed	5,278.25	2,610.25	2,790.25	14,930.95	7,128.82
	Changes in inventories of finished goods, Stock in Trade and work in progress	(2,493.40)	(603.10)	(27.72)	(4,420.85)	329.89
	Employee benefits expense	154.08	171.30	124.76	554.04	488.19
	Finance costs	57.07	151.15	91.42	374.07	371.52
	Depreciation and amortization expense	29.19	35.33	82.81	152.41	177.39
	Other expenses	620.82	151.79	286.49	1,380.76	860.88
	<b>Total expenses (II)</b>	<b>3,646.01</b>	<b>2,516.72</b>	<b>3,348.01</b>	<b>12,971.38</b>	<b>9,356.69</b>
III	<b>Profit/(loss) before tax (I-II)</b>	<b>1,444.30</b>	<b>1,061.33</b>	<b>1,548.93</b>	<b>4,250.72</b>	<b>2,688.82</b>
IV	<b>Tax expenses</b>					
	Current tax	188.78	527.73	47.19	1,180.27	757.20
	Deferred tax	148.33	18.40	(12.32)	161.64	(17.46)
	MAT Credit Entitlement	-	-	(150.72)	-	(102.71)
	<b>Total Tax expense (IV)</b>	<b>337.11</b>	<b>546.13</b>	<b>(115.85)</b>	<b>1,341.91</b>	<b>637.03</b>
V	<b>Profit/(loss) after tax for the period (III-IV)</b>	<b>1,107.19</b>	<b>515.20</b>	<b>1,664.78</b>	<b>2,908.81</b>	<b>2,051.79</b>
VI	<b>Other Comprehensive Income</b>					
	OCI that will be reclassified to P&L	(7.13)	0.34	-	(6.79)	-
	OCI Income tax of items that will be reclassified to P&L	1.70	-	-	1.70	-
	<b>Total Other Comprehensive Income (VI)</b>	<b>(5.43)</b>	<b>0.34</b>	<b>-</b>	<b>(5.09)</b>	<b>-</b>
VII	<b>Total Comprehensive Income for the period (V+VI)</b>	<b>1,101.76</b>	<b>515.54</b>	<b>1,664.78</b>	<b>2,903.72</b>	<b>2,051.79</b>
VIII	<b>Profit/(loss) after tax for the period (III-IV) attributable to:</b>					
	-Owners of the company	1,049.76	515.20	1,664.78	2,851.38	2,051.79
	-Non-Controlling Interests	57.43	-	-	57.43	-
		<b>1,107.19</b>	<b>515.20</b>	<b>1,664.78</b>	<b>2,908.81</b>	<b>2,051.79</b>
IX	<b>Total Other Comprehensive Income (VI) attributable to:</b>					
	-Owners of the company	(5.43)	0.34	-	(5.09)	-
	-Non-Controlling Interests	-	-	-	-	-
		<b>(5.43)</b>	<b>0.34</b>	<b>-</b>	<b>(5.09)</b>	<b>-</b>
X	<b>Total Comprehensive Income for the period (V+VI) attributable to:</b>					
	-Owners of the company	1,044.34	515.54	1,664.78	2,846.29	2,051.79
	-Non-Controlling Interests	57.43	-	-	57.43	-
		<b>1,101.76</b>	<b>515.54</b>	<b>1,664.78</b>	<b>2,903.72</b>	<b>2,051.79</b>
XI	<b>Details of Equity Share Capital</b>					
	Paid-Up Equity Share Capital	5,315.15	5,315.15	3,985.15	5,315.15	3,985.15
	Face Value of Equity Share Capital (Per Value)	10.00	10.00	10.00	10.00	10.00
	<b>Other Equity</b>				17,707.71	4,057.02
XII	<b>Earnings per equity share</b>					
	Basic	2.33	1.13	5.15	6.11	6.37
	Diluted	2.33	1.13	5.15	6.11	6.37

Place: Rajkot  
Date: 29-May-2026

For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



Punitkumar R. Rasadia  
Managing Director  
6696258

Naimish D Bhatt  
Chief financial officer

Meet A. Vachhani  
Whole Time Director  
6695053

Amrita Pragada  
CS & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29/05/2026  
Place: Rajkot

**Anlon Healthcare Limited**

U24230GJ2013PLC077543

Registered office: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road,

Consolidated Balance Sheet as at 31-03-2026

Rs. in Lacs (Unless stated otherwise)

Particulars	As at	As at
	31 March 2026	31 March 2025
	Audited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	5,771.36	2,281.90
Goodwill	4.79	-
Financial Assets		
Investments	97.89	-
Other non current assets	696.44	-
<b>Total Non-current Assets</b>	<b>6,570.48</b>	<b>2,281.90</b>
<b>Current assets</b>		
Inventories	11,316.34	5,026.31
Financial Assets		
Investments	1.00	90.91
Trade receivables	10,367.77	7,499.87
Cash and cash equivalents	436.59	144.96
Loans	19.46	227.96
Other financial assets	-	138.04
Other current assets	8,684.87	2,720.05
<b>Total Current Assets</b>	<b>30,826.03</b>	<b>15,848.10</b>
<b>Total Assets</b>	<b>37,396.51</b>	<b>18,130.00</b>
<b>EQUITY and LIABILITIES</b>		
Equity Share Capital	5,315.15	3,985.15
Other Equity	17,707.71	4,057.02
<b>Total Equity</b>	<b>23,022.86</b>	<b>8,042.17</b>
Non controlling interests	2,456.56	-
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	609.37	3,835.70
Provisions	36.68	24.40
Deferred tax liabilities net	514.47	222.50
<b>Total Non-current liabilities</b>	<b>1,160.52</b>	<b>4,082.60</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	3,755.90	2,819.74
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	7.66	47.68
- total outstanding dues of others	4,211.57	1,916.67
Other current liabilities	1,395.54	433.48
Provisions - current	66.06	30.46
Current Tax Liabilities, net	1,319.84	757.20
<b>Total Current liabilities</b>	<b>10,756.57</b>	<b>6,005.23</b>
<b>Total liabilities</b>	<b>11,917.09</b>	<b>10,087.83</b>
<b>Total Equity and Liabilities</b>	<b>37,396.51</b>	<b>18,130.00</b>

Place: Rajkot  
Date: 29-May-2026For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)Punitkumar R. Rasadia  
Managing Director  
6696258  
Naimish D Bhatt  
Chief financial officer  
Meet A Vachhani  
Whole Time Director  
6695053  
Amita Pragada  
Company Secretary & Compliance OfficerSIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936WDate: 29/05/2026  
Place: Rajkot

Rs. in Lacs (Unless stated otherwise)

Particulars	Note No	Rs. in Lacs (Unless stated otherwise)	
		For Period ended 31 March 2026	For Period ended 31 March 2025
		Audited	Audited
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit for the year		2,908.81	2,051.79
<b>Adjustments for:</b>			
Depreciation and amortisation		152.41	177.39
(Gain)/Loss on disposal of property, plant and equipment		-	(8.12)
(Gain)/Loss on disposal of investments		-	2.35
(Gain)/Loss on investments measured at fair value through profit and loss		-	30.46
Provision for Income tax		1,341.91	-
Provision for Gratuity		25.77	7.91
Finance Cost		374.06	371.52
Interest Income		(20.97)	-
<b>Operating profit before working capital changes</b>		<b>4,781.99</b>	<b>2,633.30</b>
<b>Adjustment for (increase) / decrease in operating assets</b>			
Trade receivables		(2,867.90)	(3,626.82)
Loans & Advances		208.49	13.80
Other financial assets		138.04	(82.23)
Inventories		(6,290.03)	(854.96)
Other assets		(6,661.26)	(1,207.30)
<b>Adjustment for (Increase) / decrease in operating liabilities</b>			
Trade payables		2,254.88	(34.88)
Employee benefit obligation		-	-
Other Liabilities		962.06	415.98
Provisions		15.32	(46.59)
<b>Cash generated from operations</b>		<b>(7,458.41)</b>	<b>(2,789.70)</b>
Income tax paid (net)		(485.59)	534.52
<b>Net cash generated by operating activities</b>		<b>(7,944.00)</b>	<b>(2,255.18)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Purchase of property, plant and equipment		(3,641.88)	(52.93)
Purchase of Goodwill		(4.79)	-
Purchase of other Investment		(7.98)	-
Proceeds from disposal of property, plant and equipment		-	323.34
Interest received		20.97	8.12
<b>Net cash (used in) / generated by investing activities</b>		<b>(3,633.68)</b>	<b>278.53</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Proceeds from short term borrowings		936.17	(32.76)
Proceeds from long term borrowings		(3,226.33)	-
Repayment of long term borrowings		-	(1,588.82)
Finance cost		(374.06)	(371.52)
Issue of Equity Shares		12,134.40	3,887.25
Non controlling interests		2,399.13	-
<b>Net cash used in financing activities</b>		<b>11,869.31</b>	<b>1,894.15</b>
Net increase / (decrease) in cash and cash equivalents		291.63	(82.50)
Cash and cash equivalents at the beginning of the year		144.96	227.45
Cash and cash equivalents acquired from subsidiaries		-	-
<b>Cash and cash equivalents at the end of the year</b>		<b>436.59</b>	<b>144.95</b>

Particulars	For Period ended 31 March 2026	For Period ended 31 March 2025
Reconciliation of Cash and Cash Equivalents with Balance Sheet:		
Cash and cash equivalents includes		
Cash on hand	358.24	144.09
Balances with Banks	78.35	0.85

Place: Rajkot  
Date: 29-May-2026

For and on behalf of Board of Directors,  
Anlon Healthcare Limited  
(CIN: U24230GJ2013PLC077543)



*(Signature)*  
Pankitkumar R. Rasadia  
Managing Director  
6696258

*(Signature)*  
Naimish D Bhatt  
Chief financial officer

*(Signature)*  
Meet A. Vachhani  
Whole Time Director  
6695053  
*(Signature)*  
Amita Pragada  
Company Secretary & Compliance Officer

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29 / 05 / 2026

**1 Corporate information**

The consolidated financial statements comprise financial statements of Anlon Healthcare Limited (the "Company") and its subsidiaries (collectively the "Group") for the year ended 31st March, 2026

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

**2 Basis of Preparation**

The Consolidated Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ('Ind AS'), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The Consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The Consolidated financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

**3 Segment Reporting**

Anlon Healthcare Limited and its Subsidiaries is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

**4 The Status of investor complaints received by the company is as follows :**

During Quarter 4 of FY 2025–26, the Company did not receive any complaints from investors. Accordingly, there were no pending investor complaints as on the end of the quarter.

**5 List of Group Companies or Subsidiary company**


Bizotic Lifescience Private Limited.  
Apiqo Organics Private Limited.

**6 IPO-related expenses incurred by the Company, to the extent they represent incremental costs directly attributable to the issuance of equity shares, have been adjusted against Securities Premium in accordance with Ind AS 32. Other expenses, not directly attributable to the issue of equity instruments, have been recognised in the Statement of Profit and Loss.**

**7 The figures for the previous year have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current year's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current year's financial statements.**

**8 Other Expenses includes operational, statutory, and administrative expenses Power Fuel, Packing Material, Factory Electricity Expenses, Freight Inward, Advertisement Expenses, Canteen and -Import Duty Expenses Etc**

For and on behalf of Board of Directors,  
Anlon Healthcare Limited

  
Punitkumar R. Rasadia  
Managing Director



Place: Rajkot  
Date: 29-May-2026

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 29 / 05 / 2026  
Place : Rajkot



May 29, 2026

<b>To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 Ref: BSE Scrip Code: 544497</b>	<b>To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL</b>
---	---

**Sub: Declaration pursuant to Regulation 33 (3) (d) of SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015 with respect to Audit Report for the year ended on March 31, 2026 with unmodified opinion.**

Respected Sir/Madam,

Pursuant to Regulation 33 (3) (d) of SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby confirm and declare that Statutory Auditors of the Company M/s. R V D & Co Chartered Accountants [FRN: 143936W] have issued Audit Report with unmodified opinion in respect of Audited Financial Results (Standalone and Consolidated) of the Company for the year ended on March 31, 2026, approved at Board Meeting held on May 29, 2026.

You are requested to take the above information on your record

Thanking You.

Yours Faithfully,

**FOR, ANLON HEALTHCARE LIMITED**

  
**PUNITKUMAR RASADIA**  
Managing Director  
DIN: 06696258

  
  
**NAIMISH BHATT**  
Chief Financial Officer

**ANLON HEALTHCARE LIMITED**

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



To,  
The Board of Directors  
Anlon Healthcare Limited  
101/102-Silver Coin Complex,  
Opp. Crystal Mall, Kalawad Road,  
Rajkot 360005, Gujarat (INDIA).

**Sub: Statutory auditor's certificate in respect of regulation under Chapter IV Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time.**

Dear Sir,

1. This certificate is issued in accordance with a request received from Anlon Healthcare Limited (the 'Company').
2. The Company was listed on National Stock Exchange of India Ltd & Bombay Stock Exchange on September 03, 2025. Pursuant to this initial public offer, the Company is required to submit a certificate with respect to utilization of the proceeds and indicate deviations, if any, from the objects stated in the offer document. Accordingly, We, R V D & Co., Chartered Accountants, the statutory auditors have been requested by the Company to verify the accompanying statement ('Annexure I') in respect of utilization of the funds for its intended purpose.
3. A copy of the accompanying statement has been attached.

**Management's responsibility**

4. The preparation of Annexure I is the responsibility of the management of the Company.
5. The preparation of the assertions for this certificate is the responsibility of the Management of the Company including the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the assertions for this certificate and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

**Our Responsibility**

6. Our responsibility is to give a limited assurance as to whether there is any deviation in the utilization of the proceeds from the objects stated in the Prospectus dated August 30, 2025 filed with the Securities and Exchange Board of India ("Prospectus").
7. We have examined the Annexure I prepared by the Company on a test check basis and initiated it for identification purposes only.
8. We have conducted our verification and issued this certificate in accordance with the Guidance Note on Reports or Certificates for Special Purposes to the extent applicable (the "Guidance Note") issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
9. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, "Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and other Assurance and Related Services Engagements" as revised from time to time.



"Level-6", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005

+91 6356 797 885

0281 - 2991685

office@cakda.in

www.cakda.in

10. We have performed the following procedures in relation to this certificate:

1. Obtained the Prospectus dated August 30, 2025 filed with the Securities and Exchange Board of India
2. Reviewed Board and auditing committee meeting minutes relating to utilisation of IPO proceeds and unutilized IPO funds
3. Obtained the audited books of accounts for the quarter ended March 31, 2026
4. Obtained necessary records and documentation to verify Annexure I
5. Obtained necessary representations from the Management of the Company.


#### Conclusion

Based on the examination and procedures performed by us as stated above and according to the representation, information and explanation given to us by the management, we certify that the proceeds have been utilized for the intended purposes and there is deviation in the utilization of the proceeds from the objects stated in the Prospectus dated August 30, 2025 filed with the Securities and Exchange Board of India.

#### Restriction on use

(iii) The certificate has been issued at the request of the Company, for submission to the National Stock Exchange and Bombay Stock Exchange pursuant to the requirements of regulation under Chapter IV Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For, R V D & Co  
Chartered Accountants  
ICAI Firm Registration No 143936W

  
Kaushal V. Dave  
(Partner)  
Membership No 174550  
UDIN: 26174550JFDYXF2845



Date: May 29, 2026  
Place: Rajkot

"Level-6", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005

+91 6356 797 885

0281 - 2991685

office@cakda.in

www.cakda.in

**Annexure -I Statement of Deviation/Variation in utilisation of funds raised**

Name of Listed Entity	Anlon Healthcare Limited
Mode of Fund Raising	Public Issue / Right Issue / Preferential Issue / QIP / Others
Date of Raising Funds	Issue Opened on: August 26, 2025 Issue Closed on: August 29, 2025
Amount Raised (In Rs.)	Rs. 12,103.00 Lacs
Report filed for Quarter/ Half Year ended	March 31, 2026
Monitoring Agency	Yes
Monitoring Agency Name, if applicable	Crisil Ratings Limited
Is there a Deviation/Variation in use of funds raised	Yes
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Yes
If Yes, Date of shareholder Approval	January 7, 2026
Explanation for the Deviation/ Variation	Company proposed to vary the object in relation to the capital expenditure and proposed expansion and proposes to deploy/ utilize an amount of Rs. 2,332.69 lakhs out of Rs. 3,071.95 lakhs for such strategic acquisitions/ mergers/ buy-outs to grow inorganically, and further upgradation of the manufacturing facilities.
Comments of the Audit Committee after review	No Comment
Comments of the Auditors, if any	No Comment



"Level-6", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005

+91 6356 797 885

0281 - 2991685

office@cakda.in

www.cakda.in

(₹ in Lakhs)

Object(S)	Amount as per final offer document	Revised Cost of objects	Amount utilised at the beginning of the reported quarter	Amount utilised during the reported quarter	Amount utilised at the end of the reported quarter	Total unutilized amount as at the end of the reported quarter	Reason for idle funds	Proposed course of actions
Funding capital expenditure requirements for the expansion of our Manufacturing Facility	3,071.95	2,332.69	1,114.99	1,956.96	3,071.95	-	-	-
Full or part repayment and/or pre-payment of certain outstanding secured borrowing (term loan) availed by our Company	500.00	500.00	500.00	-	500.00	-	-	-
Funding the Working capital requirement	4,315.00	4,315.00	4,315.00		4,315.00	-	-	-
Offer Expense	1,513.05	1,428.66	1,416.86	11.80	1,428.66	-	-	-
General corporate purposes	2,703.00	2,787.39	2,232.19	542.00	2,774.19	13.20	-	The Company will utilize the unutilized amount for the same purpose only.
<b>Total</b>	<b>12,103.00</b>	<b>12,103.00</b>	<b>9,579.04</b>	<b>2,510.76</b>	<b>12,089.80</b>	<b>13.20</b>		

\*Note: The Company obtained approval of the shareholders for variation in this object disclosed in the Offer Documents for proposed expansion through inorganic growth and further upgradation, via a postal ballot concluded on January 7, 2026.



"Level-6", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005

+91 6356 797 885

0281 - 2991685

office@cakda.in

www.cakda.in